Basic & Clinical Medicine ›› 2023, Vol. 43 ›› Issue (2): 322-326.doi: 10.16352/j.issn.1001-6325.2023.02.322

• Mini Reviews • Previous Articles     Next Articles

Progress on the role of NLRP3 inflammasome in hyperuricemic nephropathy

DAI Zhixin1*, WANG Yumin2   

  1. 1. Department of General Family Medicine, the Affiliated Hospital of Chifeng University, Chifeng 024005;
    2. Department of Respiratory and Critical Care Medicine,Aerospace Center Hospital,Peking University Aerospace School of Clinical Medicine, Beijing 100049, China
  • Received:2021-11-03 Revised:2022-04-12 Online:2023-02-05 Published:2023-02-02
  • Contact: *

Abstract: Hyperuricemic nephropathy (HN) is a common clinical complication of hyperuricemia, leading to hyperuricemia-associated renal abnormalities. The present review sheds light on the mechanistic aspects pertaining to HN, emphasizing the role of nucleotide-binding oligomerization domain leucine-rich repeat and pyrin domain-containing protein 3 (NLRP3) inflammasome activation in the occurrence and development of HN.This review recommends pharmacological inhibition of NLRP3 infammasome as a therapeutic strategy of HN treatment.

Key words: hyperuricemic nephropathy, hyperuricemia, NLRP3 inflammasome, inhibitor

CLC Number: